Immunohistochemical Expression of P63 in Ovarian Tumors among Sudanese Women
Published: 2024-01-23
Page: 14-20
Issue: 2024 - Volume 7 [Issue 1]
Ibrahim Bakhit Y. Elemam
Department of Histopathology and Cytology, Faculty of Medical Laboratory Science, Shendi University, Sudan and Department of Histopathology and Cytology, Faculty of Medical Laboratory Science, Al Neelain University, Sudan.
Eman Abd elgadir M. Elshariff
Department of Histopathology and Cytology, Faculty of Medical Laboratory Science, Al Neelain University, Sudan.
Mohammed Abdelgader Elsheikh
Department of Histopathology and Cytology, Faculty of Medical Laboratory Science, Shendi University, Sudan.
Tibyan Abd Almajed Altaher *
Department of Clinical Chemistry, Faculty of Medical Laboratory Sciences, Shendi University, Sudan.
Ghanem Mohammed Mahjaf
Department of Medical Microbiology, Faculty of Medical Laboratory Sciences, Shendi University, Sudan.
Waha Ismail Yahia Abdelmula
Biofuels Institute, School of Emergency Management, School of Environmental and Safety Engineering, Jiangsu University, Zhenjiang, Jiangsu 212013, China.
Babbiker Mohammed Taher Gorish
Department of Medical Microbiology, Faculty of Medical Laboratory Sciences, Omdurman Islamic University, Sudan.
*Author to whom correspondence should be addressed.
Abstract
Background: Ovarian cancer is a deadly illness with little understanding of its biology. The tumor suppressor p63 is a homolog gene of p53. P63 has an important role in the development and differentiation of reproductive epithelium and interacts with p53 in human tumorigenesis.
Objective: The study was aimed at assessing the immunohistochemical expression of p63 in benign and malignant epithelial ovarian tumors.
Methods: In this hospital-based analytical retrospective cross-sectional study, we evaluated at p63 immunoexpression in (80) formalin-fixed paraffin-embedded blocks from patients with ovarian tumors; 40 (50%) were malignant, and 40 (50%) were benign. Malignant samples with histological subtypes include 32 (40%) epithelial ovarian cancer samples and 8 (10%) granulosa cell tumors. We used a mouse monoclonal antibody against the p63 antigen (Dako), which identifies all p63 variations, and tumors were designated p63 positive if 5% or more cells showed nuclear immunostaining.
Results: We discovered that 90% of the samples expressing the gene were from benign ovarian tumors and 10% were from malignant ovarian tumors, with a p-value of 0.000. In terms of histological subtypes of malignant tumors, p63 expression was found in 7.5% of epithelial ovarian tumors and 2.5% of granulosa cell tumors, with a p-value of 0.792.
Conclusion: Patients with ovarian tumors are often older than 50 years old. Epithelial ovarian cancer is the most histologically significant kind of ovarian cancer. p63 expression was low in ovarian cancer, and there was no significant relationship between p63 expression and ovarian tumor subtypes or tumor grade.
Keywords: Ovarian tumor, immunohistochemical, p63, Sudan
How to Cite
References
Fisher ML, Balinth S, Mills AA. p63-related signaling at a glance. J Cell Sci. 2020;133(17):jcs228015. [PMC free article] [PubMed]
Di Como CJ, Urist MJ, Babayan I, Drobnjak M, Hedvat CV, Teruya-Feldstein J, et al. p63 expression profiles in human normal and tumor tissues. Clin Cancer Res. 2002;8(2):494–501. [PubMed] [Google Scholar]
Poli Neto OB, Candido dos Reis FJ, Zambelli Ramalho LN, Nogueira AA, de Andrade JM. p63 expression in epithelial ovarian tumors. Int J Gynecol Cancer. 2006;16(1):152–155. DOI:10.1111/j.1525-1438.2006.00290.x. [PubMed[ [CrossRef[ [Google Scholar]
Murray-Zmijewski F, Lane DP, Bourdon JC. p53/p63/p73 isoforms: an orchestra of isoforms to harmonise cell differentiation and response to stress. Cell Death Differ. 2006;13(6):962–972. DOI:10.1038/sj.cdd.4401914. [PubMed] [CrossRef] [Google Scholar]
Reis-Filho JS, Simpson PT, Fulford LG, Martins A, Schmitt FC. P63-driven nuclear accumulation of beta-catenin is not a frequent event in human neoplasms. Pathol Res Pract. 2003;199(12):785–793. DOI:10.1078/0344-0338-00497. [PubMed] [CrossRef] [Google Scholar]
Au NH, Gown AM, Cheang M, Huntsman D, Yorida E, Elliott WM, et al. P63 expression in lung carcinoma: a tissue microarray study of 408 cases. Appl Immunohistochem Mol Morphol. 2004; 12(3):240–247. DOI: 10.1097/00129039-200409000-00010. [PubMed] [CrossRef] [Google Scholar]
Bishop JA, Teruya-Feldstein J, Westra WH, Pelosi G, Travis WD, Rekhtman N. p40 (DeltaNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma. Mod Pathol. 2012;25(3): 405–415. DOI:10.1038/modpathol.2011.173. [PubMed] [CrossRef] [Google Scholar]
Kanitakis J, Chouvet B. Expression of p63 in cutaneous metastases. Am J Clin Pathol. 2007;128(5):753–758. DOI:10.1309/BD3K8U7KD969Y07U. [PubMed] [CrossRef] [Google Scholar]
Kim YW, Do IG, Park YK. Expression of the GLUT1 glucose transporter, p63 and p53 in thyroid carcinomas. Pathol Res Pract. 2006;202(11):759–765. DOI: 10.1016/j.prp.2006.07.006. [PubMed] [CrossRef] [Google Scholar]
Lin X, Zhu B, Villa C, Zhong M, Kundu S, Rohan SM, et al. The utility of p63, p40, and GATA-binding protein 3 immunohistochemistry in diagnosing micropapillary urothelial carcinoma. Hum Pathol. 2014;45(9):1824–1829. DOI:10.1016/j.humpath.2014.04.015. [PubMed] [CrossRef] [Google Scholar]
Guo HQ, Huang GL, Liu OF, Liu YY, Yao ZH, Yao SN, et al. p63 expression is a prognostic factor in colorectal cancer. Int J Biol Markers. 2012;27(3):e212–e218. DOI:10.5301/JBM.2012.9581. [PubMed] [CrossRef] [Google Scholar]
Conde E, Angulo B, Redondo P, Toldos O, Garcia-Garcia E, Suarez-Gauthier A, et al. The use of P63 immunohistochemistry for the identification of squamous cell carcinoma of the lung. PLoS One. 2010; 5(8):e12209. DOI: 10.1371/journal.pone.0012209. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
Hall BJ, Pincus LB, Yu SS, Oh DH, Wilson AR, McCalmont TH. Immunohistochemical prognostication of Merkel cell carcinoma: p63 expression but not polyomavirus status correlates with outcome. J Cutan Pathol. 2012;39(10):911–917. DOI:10.1111/j.1600-0560.2012.01964.x. [PubMed] [CrossRef] [Google Scholar]
Vrabie CD, Terzea D, Petrescu A, Waller M. The histopathology analysis of the diffuse sclerosing variant of the papillary carcinoma of the thyroid: a distinctive and rare form. Romanian J Morphol Embryol. 2009;50(4):743–748. [PubMed] [Google Scholar]
Koyuncuer A. Immunohistochemical expression of p63, p53 in urinary bladder carcinoma. Indian J Pathol Microbiol. 2013; 56(1):10–15. DOI: 10.4103/0377-4929.116141. [PubMed] [CrossRef] [Google Scholar]
Carneiro FP, Ramalho LN, Britto-Garcia S, Ribeiro-Silva A, Zucoloto S. Immunohistochemical expression of p16, p53, and p63 in colorectal adenomas and adenocarcinomas. Dis Colon Rectum. 2006;49(5):588–594. DOI:10.1007/s10350-006-0515-4. [PubMed] [CrossRef [Google Scholar]
Zhang N, Huo Q, Wang X, Chen X, Long L, Guan X, et al. A genetic variant in p63 (rs17506395) is associated with breast cancer susceptibility and prognosis. Gene. 2014;535(2):170–176. DOI:10.1016/j.gene.2013.11.038. [PubMed] [CrossRef] [Google Scholar]
Doubeni, C; Doubeni, A; and Myers, A. Diagnosis and Mangement of Ovarian Cancer. American Family Physician. 2016; 1:93(11):937-944.
Dafalla, OA. Hsin-Yi, W., Ahmed, ME., Elgaylani, AE. Mohamed, E., SI. And Mohammed, IM . Incidence and survival rates of ovarian cancer in low-income women in Sudan. Molecular and Clinical Oncology. 2016;5:823-828.
Jermaine, IGC. Kathryn, M. And Felicity, M. New perspectives on targeted therapy in ovarian cancer. International Journal of Women's Health. 2015;7:189-203.
Reis-Filho JS, Simpson PT, Martins A, Preto A, Gartner F, Schmitt FC. Distribution of p63, cytokeratins 5/6 and cytokeratin 14 in 51 normal and 400 neoplastic human tissue samples using TARP-4 multi-tumor tissue microarray. Virchows Arch. 2003; 443:122–32.
Reis-Filho JS, Simpson PT, Martins A, Preto A, Gartner F, Schmitt FC. Distribution of p63, cytokeratins 5/6 and cytokeratin 14 in 51 normal and 400 neoplastic human tissue samples using TARP-4 multi-tumor tissue microarray. Virchows Arch. 2003; 443(2):122–132. DOI:10.1007/s00428-003-0859-2. [PubMed] [CrossRef] [Google Scholar]
Tsoref D, Panzarella T. et al.. "Aspirin in prevention of ovarian cancer: are we at the tipping point?" J Natl Cancer Inst. 2014; 106(2): djt453.
Stachs A, Hartmann S. et al.. "Preservation of Fertility or Ovarian Function in Patients with Breast Cancer or Gynecologic and Internal Malignancies." Geburtshilfe Frauenheilkd. 2017;77(8):861-869.
Boorjian S. Commentary on "Reproductive factors and kidney cancer risk in 2 US cohort studies, 1993-2010. Karami S, Daugherty SE, Schonfeld SJ, Park Y, Hollenbeck AR, Grubb RL 3rd, Hofmann JN, Chow WH, Purdue MP, Occupational and Environmental Epidemiology Branch, Division of Cancer Epidemiology and Genetics, Department of Health and Human Services, National Cancer Institute, National Institutes of Health, Bethesda, MD. Am J Epidemiol 2013; 177(12):1368-77. [Epub 2013 Apr 26]. Doi:10.1093/aje/kws406." Urol Oncol 32(6): 932-933.
Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, et al . Cancer statistics, 2006. CA Cancer J Clin. 2006;56:106-30.
DO Abuidris D, HY Weng, AM Elhaj, EA Eltayeb, M Elsanousi, RS Ibnoof, and SI Mohammed. Incidance and survival rates of ovarian cancer in low-income women in Sudan. Molecular and Clinical Oncology. 2016;5 (6):823-828.
Ramos-Vara JA. Technical Aspects of Immunohistochemistry Vet Pathol. 2005; 42:405–426.